First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.04 USD -0.95% Market Closed
Updated: May 29, 2024

Adaptimmune Therapeutics PLC
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Adaptimmune Therapeutics PLC
Long-Term Debt Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Long-Term Debt
$75.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Long-Term Debt
$30.8m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Long-Term Debt
£48m
CAGR 3-Years
-8%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Long-Term Debt
£273.6m
CAGR 3-Years
30%
CAGR 5-Years
21%
CAGR 10-Years
12%

See Also

What is Adaptimmune Therapeutics PLC's Long-Term Debt?
Long-Term Debt
0 USD

Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Long-Term Debt amounts to 0 USD.